ClinicalTrials.gg
CompletedNCT06057168GDX-44-016Updated Jan 29, 2026Results posted

Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas

A Phase 3 interventional study of Elucirem and Dotarem in Brain Tumor, Primary and Brain Tumor, Recurrent, sponsored by Guerbet. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Brain Neoplasms with a site in Hungary — 1 open to participants now, 1 under way, none of them phase 3. Brain Neoplasms · Hungary.

Enrollment
8th of 11
138 · median 298
Started
2023
the only one that year
Phase 3
9 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Guerbet

Among the 12 studies in Brain Neoplasms with a site in Hungary, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 3, and was the 12th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

1 of the 12 studies in Brain Neoplasms with a site in Hungary is open now. Recruiting first, the newest first:

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Brain Neoplasms with a site in Hungary, or all of them as a file.
02

Study summary

This trial aimed to study the performance of Elucirem (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.

Read the detailed description

The trial was designed as a prospective, multi-center, randomized, controlled and parallel group comparison.

This study aimed to enrol 138 patients in Italy, Poland and Hungary.

During the course of the trial, patient underwent a DSC-MRI perfusion using Elucirem or Dotarem. A safety visit was performed 1 day after the MRI visit. Confirmation of tumor grade diagnosis, if available, was collected up to 30 days after visit 2. Primary end point was assessed by independent off-site blinded readers.

03

Conditions studied

  • Brain Tumor, Primary
  • Brain Tumor, Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male adult patient (patient having reached legal majority age).
  2. Patient with naive or recurrent primary glial tumor detected at a previous Computed Tomography (CT) or MR imaging, and scheduled for a follow-up contrast-enhanced MRI. Tumor grade (confirmed or highly suspected) should be available in patients' medical records.
  3. Patient or, if the patient is unable to provide , the patient's legally acceptable representative and/or impartial witness, having read the information and having provided patient's consent to participate in writing by dating and signing the informed consent prior to any trial related procedure being conducted.
  4. Patient affiliated to national health insurance according to local regulatory requirements.

Exclusion criteria

Exclusion Criteria:

  1. Patient with known (s) to the use or with known sensitivity to one of the products under investigation or to other Gadolinium-Based Contrast Agents (GBCA) (such as , post-contrast acute kidney injury).
  2. Patient presenting with any contraindication to MRI examinations.
  3. Post treatment patient presenting with pseudo-progression instead of tumor recurrency.
  4. Patient presenting with severe renal insufficiency, defined as an estimated (eGFR) \< 30 mL/min/1.73 m² assessed within 1 week prior to contrast agent injection.
  5. Patient having received any contrast agent (for MRI or CT) within 3 days prior to IMP administration or scheduled to receive any contrast agent within 24 hours after IMP administration.
  6. Pregnant female patient (a female patient of or with amenorrhea for less than 12 months must have a negative pregnancy test within 1 day prior to trial MRI and must be using medically approved method until the last trial visit).
  7. Patient having received any medicinal product within 7 days prior to trial entry or scheduled to receive any investigational treatment in the course of the trial.
  8. Patient previously randomized in this trial.
  9. Patient with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the patient's safety or her/his ability to participate in the trial.
  10. Patient unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits and/or unlikelihood of completing the trial.
  11. Patient related to the investigator or any other trial staff or relative directly involved in the trial conduct.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Elucirem

    Patient underwent a DSC-MRI perfusion using Elucirem.

    Drug: Elucirem

  • Active comparator
    Dotarem

    Patient underwent a DSC-MRI perfusion using Dotarem.

    Drug: Dotarem

Interventions

  • Intravenous administration

    Also known as: gadopiclenol

  • Intravenous administration

    Also known as: gadoterate meglumine, gadoteric acid

06

What researchers measure

Primary outcomes

  1. Diagnostic Quality of Cerebral Blood Volume (CBV) Map of Dynamic Susceptibility Contrast MRI (DSC-MRI) Perfusion

    Diagnostic quality of the CBV map obtained from DSC-MRI perfusion for each patient was assessed by the two off-site blinded readers using the following scale (poor, fair, good or excellent) and by a consensus in case of discordance between the two readers. The proportion of patients with "excellent" or "good" diagnostic quality images of Elucirem group was compared to that of Dotarem group. 124 patients (60 with Elucirem and 64 with Dotarem) who had diagnostic CBV map and without major protocol deviation were included in the per-protocol primary analysis.

    Time frame: From beginning to end of procedure for DSC-MRI perfusion using Elucirem or Dotarem

07

Results

Posted Jan 29, 2026

Participant flow

A total of 141 patients were screened in 10 centers from three countries: 76 from four centers in Hungary, 48 from four centers in Italy and 17 from two centers in Poland.

Participant flow — Overall Study
MilestoneEluciremDotarem
Started6969
Completed6769
Not completed20
Withdrew: Adverse event20

Outcome measures

PrimaryDiagnostic Quality of Cerebral Blood Volume (CBV) Map of Dynamic Susceptibility Contrast MRI (DSC-MRI) Perfusion

Diagnostic quality of the CBV map obtained from DSC-MRI perfusion for each patient was assessed by the two off-site blinded readers using the following scale (poor, fair, good or excellent) and by a consensus in case of discordance between the two readers. The proportion of patients with "excellent" or "good" diagnostic quality images of Elucirem group was compared to that of Dotarem group. 124 patients (60 with Elucirem and 64 with Dotarem) who had diagnostic CBV map and without major protocol deviation were included in the per-protocol primary analysis.

Time frame:
From beginning to end of procedure for DSC-MRI perfusion using Elucirem or Dotarem
Reported as:
Count of participants · Participants
Diagnostic Quality of Cerebral Blood Volume (CBV) Map of Dynamic Susceptibility Contrast MRI (DSC-MRI) Perfusion
ParticipantsEluciremDotarem
Diagnostic Quality of Cerebral Blood Volume (CBV) Map of Dynamic Susceptibility Contrast MRI (DSC-MRI) Perfusion5863
Statistical analysis
  • Elucirem vs Dotarem · Two-sided 95% confidence interval (ci): -0.018 · 95% CI -0.089 to 0.053Construction of a two-sided 95% CI around the difference in proportion of patients with images of excellent or good diagnostic quality CBV map

Adverse events

Collected over From the beginning of patient's participation in the trial (Informed Consent Form signature) until the end of the participation (1 day after IMP administration for the patients without biopsy or surgery done, maximum 30 days after IMP administration for the patients with biopsy or surgery done).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elucirem0/67 (0%)0/67 (0%)3/67 (4.5%)
Dotarem0/69 (0%)0/69 (0%)2/69 (2.9%)
Most frequent other events
Most frequent other events
EventEluciremDotarem
Incorrect dose administeredInjury, poisoning and procedural complications2/670/69
DiarrhoeaGastrointestinal disorders1/670/69
NauseaGastrointestinal disorders1/670/69
VomitingGastrointestinal disorders1/670/69
Incorrect dose administered by deviceInjury, poisoning and procedural complications0/671/69
HeadacheNervous system disorders0/671/69

Baseline characteristics

Baseline description for safety population (patients received an injection of contrast agent): A total of 136 patients including 67 patients who received an injection of Elucirem and 69 patients who received an injection of Dotarem.

Age, Categorical
Age, Categorical(Participants)EluciremDotaremTotal
<=18 years000
Between 18 and 65 years5151102
>=65 years161834
Age, Continuous
Age, Continuous(years)EluciremDotaremTotal
Mean54.9 ± 14.2354.6 ± 14.7154.8 ± 14.42
Sex: Female, Male
Sex: Female, Male(Participants)EluciremDotaremTotal
Female233053
Male443983
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EluciremDotaremTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6768135
More than one race000
Unknown or Not Reported000
08

Study locations

11 sites
  • Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá
    Budapest, Hungary
  • Semmelweis Egyetem - Neurologiai Klinika
    Budapest, Hungary
  • Debreceni Egyetem
    Debrecen, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pécs, Hungary
  • Ospedale Papa Giovanni XXIII
    Bergamo, Italy
  • Ospedale San Raffaele- Neuroradiologia
    Milan, Italy
  • IRCCS C.Mondino, Istituto Neurologico Nazionale, Fondazione
    Pavia, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, Italy
  • Uniwersyteckie Centrum Kliniczne w Gdansku
    Gdansk, Poland
  • Szpital Specjalistyczny im.L.Rydygiera
    Krakow, Poland
  • Independent Public Teaching Hospital no 1 Department of Interventional Radiology and Diagnostic Imaging
    Lublin, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2024, 14 months.

Results were first posted in Jan 2026, 1 year 2 months after primary completion.

Of 56 phase 3 interventional studies under Brain Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 269. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 28, 2023
StartActual
Sep 7, 2023
Primary completionActual
Nov 28, 2024
CompletionActual
Nov 28, 2024
Results first posted
Jan 29, 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06057168
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Sep 7, 2023
Primary completion
Nov 28, 2024
Completion
Nov 28, 2024
Results posted
Jan 29, 2026
Last update
Jan 29, 2026

Study contacts

Frantz Hebert
study director · Guerbet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion